MD1561Z - Метод комплексного лечения инфекции вирусом SARS-CoV-2 - Google Patents
Метод комплексного лечения инфекции вирусом SARS-CoV-2 Download PDFInfo
- Publication number
- MD1561Z MD1561Z MDS20210013A MDS20210013A MD1561Z MD 1561 Z MD1561 Z MD 1561Z MD S20210013 A MDS20210013 A MD S20210013A MD S20210013 A MDS20210013 A MD S20210013A MD 1561 Z MD1561 Z MD 1561Z
- Authority
- MD
- Moldova
- Prior art keywords
- days
- day
- ozone
- mixture
- once
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 18
- 241001678559 COVID-19 virus Species 0.000 title claims abstract description 12
- 230000009385 viral infection Effects 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title claims description 20
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000000203 mixture Substances 0.000 claims abstract description 27
- OGIIWTRTOXDWEH-UHFFFAOYSA-N [O].[O-][O+]=O Chemical compound [O].[O-][O+]=O OGIIWTRTOXDWEH-UHFFFAOYSA-N 0.000 claims abstract description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 10
- 238000009098 adjuvant therapy Methods 0.000 claims abstract description 6
- 229940004856 acetylcysteine 600 mg Drugs 0.000 claims abstract description 5
- 150000001413 amino acids Chemical class 0.000 claims abstract description 5
- 229940068661 cefuroxime 500 mg Drugs 0.000 claims abstract description 5
- 229960001145 deflazacort Drugs 0.000 claims abstract description 5
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 claims abstract description 5
- 230000037149 energy metabolism Effects 0.000 claims abstract description 5
- 229960005153 enoxaparin sodium Drugs 0.000 claims abstract description 5
- 230000002178 gastroprotective effect Effects 0.000 claims abstract description 5
- 230000000968 intestinal effect Effects 0.000 claims abstract description 5
- 230000002035 prolonged effect Effects 0.000 claims abstract description 5
- 229940125723 sedative agent Drugs 0.000 claims abstract description 5
- 239000000932 sedative agent Substances 0.000 claims abstract description 5
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 claims abstract description 5
- 229940003827 azithromycin 500 mg Drugs 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 208000035473 Communicable disease Diseases 0.000 abstract description 2
- 208000025721 COVID-19 Diseases 0.000 description 17
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 13
- 239000001301 oxygen Substances 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 230000002354 daily effect Effects 0.000 description 7
- 230000000840 anti-viral effect Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 208000004987 Macrophage activation syndrome Diseases 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000141 anti-hypoxic effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- LELAOEBVZLPXAZ-UHFFFAOYSA-N iberin Chemical compound CS(=O)CCCN=C=S LELAOEBVZLPXAZ-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940046732 interleukin inhibitors Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- -1 lipid peroxides Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- PVBQYTCFVWZSJK-UHFFFAOYSA-N meldonium Chemical compound C[N+](C)(C)NCCC([O-])=O PVBQYTCFVWZSJK-UHFFFAOYSA-N 0.000 description 1
- 229960002937 meldonium Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000026326 mitochondrial transport Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 230000035781 nonspecific defense system Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000013878 renal filtration Effects 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- 230000035886 specific defense system Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к медицине, в частности к инфекционным болезням и пневмологии, и может быть использовано для комплексного лечения инфекции вирусом SARS-CoV-2.Сущность изобретения состоит в том, что вводят азитромицин 500 мг, один раз в день, в течение 9 дней, цефуроксим 500 мг по 1 таблетке 2 раза в день, в течение 14 дней, раствор эноксапарина натрия по 0,4 мл 2 раза в день, подкожно, в течение 5 дней, дефлазакорт 45 мг, в течение 3 дней, затем 37,5 мг, в течение 3 дней, затем 30 мг, в течение 5 дней, затем 22,5 мг, в течение 5 дней, затем 15 мг, в течение 6 дней, ацетилцистеин 600 мг один раз в день, в течение 10 дней; адъювантную терапию с применением гастропротекторных препаратов, препаратов, воздействующих на энергетический обмен организма, аминокислот, препаратов для улучшения кишечного биоценоза и седативных средств; одновременно вводят внутривенно 500 мл озонированного раствора 0,9% NaCl с кислородно-озоновой смесью, с концентрацией озона 5 мкг/мл, один раз в день, в течение 7 дней, затем продлевают указанным раствором с концентрацией озона 3 мкг/мл один раз в день, в течение 5 дней, также выполняют назальные и ректальные инсуффляции кислородно-озоновой смесью, при этом назальные инсуффляции проводят смесью с концентрацией озона 10 мкг/мл, которые проводят 5…7 мин, ежедневно, в течение 12 дней, а ректальные инсуффляции проводят введением 150…300 мл смеси с концентрацией озона 10…25 мкг/мл, ежедневно, в течение 7 дней.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20210013A MD1561Z (ru) | 2021-02-25 | 2021-02-25 | Метод комплексного лечения инфекции вирусом SARS-CoV-2 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20210013A MD1561Z (ru) | 2021-02-25 | 2021-02-25 | Метод комплексного лечения инфекции вирусом SARS-CoV-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD1561Y MD1561Y (ru) | 2021-08-31 |
| MD1561Z true MD1561Z (ru) | 2022-03-31 |
Family
ID=77635756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20210013A MD1561Z (ru) | 2021-02-25 | 2021-02-25 | Метод комплексного лечения инфекции вирусом SARS-CoV-2 |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD1561Z (ru) |
-
2021
- 2021-02-25 MD MDS20210013A patent/MD1561Z/ru active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MD1561Y (ru) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bocci | Scientific and medical aspects of ozone therapy. State of the art | |
| Bocci | Ozone: a new medical drug | |
| Hernández et al. | Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study | |
| Hernández et al. | Potential role of oxygen–ozone therapy in treatment of COVID-19 pneumonia | |
| Bocci | The case for oxygen-ozonetherapy | |
| Bocci et al. | Oxygen-ozone therapy in medicine: an update | |
| Di Fenza et al. | High-dose inhaled nitric oxide in acute hypoxemic respiratory failure due to COVID-19: a multicenter phase II trial | |
| JP2003524630A5 (ru) | ||
| Jung et al. | A fatal case of intravascular coagulation after bee sting acupuncture | |
| Di Paolo et al. | Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease | |
| Bocci | The clinical application of ozonetherapy | |
| Ottani et al. | Protective effects of the melanocortin analog NDP-α-MSH in rats undergoing cardiac arrest | |
| Razzaq et al. | Utilization of ozone as a complementary therapy for COVID-19 patients | |
| Omar et al. | Nebulized nitroglycerin in children with pulmonary hypertension secondary to congenital heart disease | |
| Zhao et al. | Extracorporeal membrane oxygenation combined with hemoperfusion to assist in the rescue of aconitine poisoning: A case report | |
| MD1561Z (ru) | Метод комплексного лечения инфекции вирусом SARS-CoV-2 | |
| Thorp et al. | Novel therapy for COVID-19 does intravenous ozonated-saline affect blood and tissue oxygenation | |
| El Shehaby et al. | The emerging therapeutic role of some pharmacological antidotes in management of COVID-19 | |
| LUCA et al. | OF COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY INFECTION WITH SARS-COV-2 VIRUS IN ELDERLY PATIENTS | |
| JP2007507528A (ja) | 四量体酸素を含む方法、組成物、装置 | |
| RU2203066C2 (ru) | Способ детоксикации организма | |
| Pisano et al. | Old issues and new challenges in cardiothoracic anesthesiology: work in progress… | |
| Totolici et al. | The impact of ozone therapy on antioxidant status and quality of life in palliative care-exploratory study | |
| EA001147B1 (ru) | Лекарственный препарат для терапевтического лечения вирусного гепатита | |
| Bocci et al. | Ozone therapy in critical patients. Rationale of the therapy and proposed guidelines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued |